US EditionNuevocor Closes US$45 Million Series B Financing for Clinical Development of Novel Mechanobiology-Centered Therapy for Cardiomyopathy
- Nuevocor, a biotechnology company based in Singapore at the IND stage, secured $45 million in a Series B fundraising round on May 6, 2025, to advance the development of its innovative treatment for cardiomyopathy.
- This funding round occurred due to Nuevocor's focus on treating LMNA-related dilated cardiomyopathy, a severe genetic heart disease with rapid progression and no effective therapies.
- The funds raised will enable the launch of an initial human Phase 1/2 clinical study of NVC-001, an AAV-based gene therapy targeting mechanobiological processes, with trial sites located throughout the U.S. And Europe.
- NVC-001 showed strong preclinical results with high transduction, dramatic survival benefits, and a clean safety profile, while CEO Dr. Yann Chong Tan stated they are "delighted to secure this significant financing milestone."
- The $45 million Series B funding round, led by Kurma Partners and Angelini Ventures joining as new investors, will enable Nuevocor to advance its lead candidate NVC-001 through early clinical trials and supports the company’s expansion into international markets, including Europe.
40 Articles
40 Articles
InsideNoVA.com
Nuevocor Closes US$45 Million Series B Financing for Clinical Development of Novel Mechanobiology-Centered Therapy for Cardiomyopathy
– Round co-led by new investors, Kurma Partners and Angelini Ventures, with significant participation from existing investors EDBI, ClavystBio, and Boehringer Ingelheim Venture Fund
Nuevocor Closes US$45M Series B Financing
Nuevocor, a Singapore-based IND-stage biotechnology company developing cures for cardiomyopathies, raised US$45M in Series B funding. The round was led by Kurma Partners and Angelini Ventures, with participation from existing investors EDBI, ClavystBio and Boehringer Ingelheim Venture Fund, alongside Highlight Capital and SEEDS Capital. The company intends to use the funds to support the Phase […] The post Nuevocor Closes US$45M Series B Financi…
Singapore's Nuevocor raises $45M Series B for Novel Cardiomyopathy therapy development
Nuevocor, a Singapore-headquartered IND-stage biotechnology company developing cures for cardiomyopathies driven by aberrant mechanobiology, has announced the successful completion of $45 million Series B financing. The round was co-led by Kurma Partners and Angelini Ventures, with significant participation from existing investors EDBI, ClavystBio and Boehringer Ingelheim Venture Fund, alongside Highlight Capital and SEEDS Capital, Nuevocor said…
Coverage Details
Bias Distribution
- 48% of the sources are Center
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
